Influenza vaccine is recommended yearly for recipients after the sixth month of BMT. Although a higher risk of complications of influenza is expected to occur in BMT patients, no study has addressed the clinical efficacy of influenza vaccination in this setting. Focusing on the clinical benefits of influenza vaccination, we evaluated the risk factors for influenza infection in a cohort of 177 BMT recipients followed up for 1 year. Influenza was diagnosed in 39 patients. Multivariate analyses showed that seasonal exposure and more aggressive conditioning regimens were independently associated with increased risk for influenza. Influenza vaccination and steroid use showed a protective role. Of the 43 patients who had received BMT longer than 6 months, 19 were vaccinated (compliance rate ¼ 44.2%) and vaccine efficacy was 80%. We conclude that influenza vaccination plays an important role in protecting BMT recipients against influenza and all efforts should be made to ensure good compliance with vaccination. Bone Marrow Transplantation (2005) 36, 897-900.
Influenza continues to cause annual worldwide epidemics and a higher risk of complications, such as influenza pneumonia, are expected to occur in transplant patients. Historically, the incidence of influenza pneumonia in BMT recipients has varied from 9.5 to 75% in different studies. [1] [2] [3] [4] Vaccination is one of the strategies currently available for the control of influenza and its complications in this setting. The effectiveness of influenza vaccine depends primarily on the age and immunocompetence of the vaccine recipient and the degree of similarity between the viruses in the vaccine and those in circulation. When the vaccine and circulating viruses are antigenically similar, influenza vaccine is expected to prevent influenza illness in approximately 70-90% of healthy persons aged less than 65 years. 5 In HSCT recipients, influenza vaccination studies have focused on serological response end points and have showed a poor response in patients vaccinated within 6 months of transplantation. 6 Therefore, inactivated influenza vaccine has been recommended annually for patients after the sixth month of transplantation. [6] [7] [8] The high rate of influenza infections observed in our BMT program 9 raised concerns about the efficacy of influenza vaccine and also about patient compliance with influenza vaccination. Thus, we retrospectively reviewed vaccination records to evaluate the risk factors for acquiring influenza, patient compliance with yearly influenza vaccination and the efficacy of influenza vaccine from the perspective of clinical response end points.
Patients and methods

Patients and RV diagnosis
A total of 177 BMT recipients, followed up at the BMT Program of the University of Sa˜o Paulo Medical School, with respiratory symptoms and at least one nasal wash (adult patients) or nasal aspirate (children) taken over a 1-year interval were evaluated. Samples were routinely taken from symptomatic patients only. A total of 775 samples were taken, mean 4.3 (1-19) per patient. Influenza was diagnosed by direct immunofluorescence assay (Imagen s DAKO, Cambridgeshire, UK) according to the manufacturer's instructions.
To access the risk factors for acquisition of influenza, the following variables were retrospectively reviewed from patients' charts: seasonal exposure, time after transplant, influenza vaccination status and steroid therapy at the time of sample collection. Patient characteristics are shown in Table 1 .
Definitions
Seasonal exposure to influenza viruses was categorized as high or low according to the period when the nasal wash sample was taken (Fall-Winter or Spring-Summer, respectively).
Vaccination policy
After the 6th month of BMT, influenza vaccination is offered annually to all patients during six consecutive months starting in the beginning of Fall. Patients received one dose of influenza vaccine (A/New Caledonia/20/99 (H1N1), A/Moscow/10/99 (H3N2), B/Sichuan/379/99) and were asked to report any side effect by phone call or directly to the pharmacist or nurses assisting the BMT program.
Statistical analysis
Vaccine efficacy (VE) was determined by the formula: VE ¼ ((r 0 -r 1 ):r 0 ); where r 0 is the rate in unvaccinated and r 1 the rate in vaccinated patients. Compliance with influenza vaccination was evaluated in 43 patients transplanted longer than 6 months, where vaccination had been advised.
Risk factors for acquisition of influenza infection were evaluated by univariate and multivariate analysis. The following variables were analyzed: gender, donor match, underlying disease, conditioning regimen, seasonal risk (high or low), time after transplant (o180 days or X180 days), graft-versus-host disease, steroid therapy, and influenza vaccination status. Variables showing a P-value o0.20 on univariate analysis were included in the multivariate model. Pp0.05 was considered statistically significant. Statistical software SPSS version 11.0 was used for the analysis.
Results
Influenza A or B was diagnosed in 39 patients (nine autologous, 30 allogeneic BMT recipients).
In all, 134 patients were within the first 6 months after BMT and were not eligible for influenza vaccination. Of these, 25 (18.6%) acquired influenza. The remaining 43 patients had undergone BMT longer than 6 months previously and were, therefore, eligible to receive influenza vaccine (Figure 1 ). In total, 19 patients were vaccinated and two acquired influenza (r 1 ¼ 0.10). Compliance with vaccination was 44.2%. Among the remaining 24 unvaccinated patients (due to low compliance with the vaccination program), influenza was diagnosed in 12 (r 0 ¼ 0.50). VE was 80% ((r 0 Àr 1 ):r 0 ).
On univariate analysis, patients with respiratory symptoms during the influenza season and those within the first 6 months of transplantation were more likely to acquire influenza infection (P ¼ 0.001 and 0.056, respectively). Considering only the 43 patients after the sixth month of BMT, influenza vaccine significantly reduced the occurrence of influenza in this group (P ¼ 0.015).
On multivariate analysis, seasonal exposure and conditioning regimens including TBI and melphalan/busulfan were independently associated with increased risk for influenza, whereas influenza vaccine and steroid therapy showed a protective role (Table 2) . Gender, BMT type, underlying disease and graft-versus-host disease were not associated with risk of influenza infection. 10 who recently observed an increased risk of influenza in patients transplanted during the influenza season, in those with advanced disease and in females. Patients conditioned with more aggressive regimens such as busulfan and melphalan and those including TBI were also more likely to acquire influenza in the present series. This observation may reflect the degree of immunosuppression and/or the impact of those regimens on the integrity of respiratory mucosae and local immunity.
Of note on multivariate analyses, steroid use and influenza vaccination showed as independent factors preventing the acquisition of influenza.
After adjusting for the time after transplant, the apparent protective role of steroid use in the acquisition of influenza is a surprising result. However, other authors have recently observed that the use of corticosteroids reduces the risk of progression of influenza from the upper to the lower respiratory tract. In that series, the authors hypothesized that steroids may promote a salutary immunomodulation in some circumstances. 10 Thus, in opposition to the deleterious effects of aggressive conditioning regimens, which promoted the risk for influenza infection in the present study, the use of corticosteroids could possibly restore part of respiratory mucosa integrity and improve local immunity. More studies are needed to confirm these findings.
The beneficial effect of influenza vaccination observed in the present study encourages preventive policies in this population. Influenza vaccination studies in BMT recipients have focused on serological end points and showed poor serological responses, irrespective of the source of stem cells (marrow or peripheral blood). 6, 7 A longer interval between BMT and influenza vaccination has been associated with a better serological response, vaccination of BMT recipients before the sixth month of transplantation being totally ineffective. 6 Seroconversion is also more likely to occur in autologous BMT or PBSCT in comparison to allogeneic BMT or PBSCT recipients. 7 Although no previous study has addressed the clinical efficacy of influenza vaccine, yearly vaccination of BMT recipients is recommended in most centers, before respiratory virus season. In the present study, serological response was not assessed. However, considering only patients at higher seasonal risk and transplanted longer than 6 months, we observed an 80% rate of clinical efficacy of influenza vaccine, similar to the rates observed in healthy adults under 65 years old. Unfortunately, regardless of having an active long-term follow-up program, we also observed a surprisingly low compliance with influenza vaccination (44.2%) in our BMT recipients.
Since 2000, the number of influenza vaccine doses per 1000 persons in Brazil has risen to levels similar to those in many Western Europe countries. 11 This increase may reflect the successful efforts of the Brazilian Health Ministry in the vaccination campaign for the elderly, but not in other highrisk populations. Indeed, worldwide, health-care workers' (HCWs') compliance with influenza vaccination has been disappointing, varying from 2 to 36% in different series. 12 Perhaps the greatest misconception about the vaccine is that it may actually cause the recipient to acquire influenza. 12 This belief may influence the HCWs' willingness to counsel patients about vaccination.
Information on the clinical efficacy of influenza vaccine provided by the present study should encourage BMT centers to revise their policies on influenza control and exhort their HCW not only to accept the vaccine but also to inform and guide patients and family caregivers to be vaccinated.
It is important to highlight that a substantial number of BMT recipients in the present study (n ¼ 76) were within 6 months of transplantation and around 28% of them acquired influenza. Since vaccine effectiveness is limited (if any) during this period, other strategies such as vaccination of contacts and pre-emptive or prophylactic therapy should be considered especially during influenza A and/or B outbreaks, as recommended to other high-risk patients. 13 Pre-emptive oseltamivir seemed to play some role in protecting patients from developing influenza pneumonia, 9, 10 but controlled studies are needed to confirm such data. Postponing BMT is an alternative to be considered on an individual basis. Other strategies such as donor vaccination deserve further investigation.
We concluded that influenza vaccination plays an important role in the control of influenza in BMT recipients and all efforts should be made to ensure compliance with this policy.
